Laura A Walker

US Patent:

20230027965, Jan 26, 2023

Filed:

Jul 15, 2021

Appl. No.:

17/376276

Inventors:

- Seattle WA, US
- La Jolla CA, US
- New York NY, US
Stephen Kaminsky - Bronx NY, US
Steven Frey - Redmond WA, US
Ole Olsen - Everett WA, US
Jennifer Mitcham - Redmond WA, US
Matthew Moyle - Redmond WA, US
Sanjay K. Phogat - Frederick MD, US
Dennis R. Burton - La Jolla CA, US
Laura Majorie Walker - San Diego CA, US
Pascal Raymond Georges Poignard - San Diego CA, US
Wayne Koff - Stony Brook NY, US
Melissa Danielle De Jean De St. Marcel Simek-Lemos - Brooklyn NY, US

International Classification:

C07K 16/10
A61P 31/18
A61K 39/21

Abstract:

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

US Patent:

20200024330, Jan 23, 2020

Filed:

Oct 2, 2019

Appl. No.:

16/591175

Inventors:

- Seattle WA, US
- La Jolla CA, US
- New York NY, US
Stephen Kaminsky - Bronx NY, US
Steven Frey - Redmond WA, US
Ole Olesen - Everett WA, US
Jennifer Mitchum - Redmond WA, US
Matthew Moyle - Redmond WA, US
Sanjay K. Phogat - Frederick MD, US
Dennis R. Burton - La Jolla CA, US
Laura Majorie Walker - San Diego CA, US
Pascal Raymond Georges Poignard - San Diego CA, US
Wayne Koff - Stony Brook NY, US
Melissa Danielle De Jean De St. Marcel Simek-Lemos - Brooklyn NY, US

International Classification:

C07K 16/10
A61K 39/21
A61P 31/18

Abstract:

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided

US Patent:

20180057570, Mar 1, 2018

Filed:

Sep 12, 2017

Appl. No.:

15/701679

Inventors:

- Seattle WA, US
- La Jolla CA, US
- New York NY, US
Stephen Kaminsky - Bronx NY, US
Steven Frey - Redmond WA, US
Ole Olsen - Everett WA, US
Jennifer Mitcham - Redmond WA, US
Matthew Moyle - Redmond WA, US
Sanjay K. Phogat - Edison NJ, US
Dennis R. Burton - La Jolla CA, US
Laura Majorie Walker - San Diego CA, US
Pascal Raymond Georges Poignard - San Diego CA, US
Wayne Koff - Stony Brook NY, US
Melissa Danielle De Jean De St. Marcel Simek-Lemos - Brooklyn NY, US

International Classification:

C07K 16/10
A61K 39/00

Abstract:

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.

US Patent:

20160264649, Sep 15, 2016

Filed:

May 12, 2016

Appl. No.:

15/152630

Inventors:

- Seattle WA, US
- La Jolla CA, US
- New York NY, US
Stephen Kaminsky - Bronx NY, US
Steven Frey - Redmond WA, US
Ole Olsen - Everett WA, US
Jennifer Mitcham - Redmond WA, US
Matthew Moyle - Redmond WA, US
Sanjay K. Phogat - Edison NJ, US
Dennis R. Burton - La Jolla CA, US
Laura Majorie Walker - San Diego CA, US
Pascal Raymond Georges Poignard - San Diego CA, US
Wayne Koff - Stony Brook NY, US
Melissa Danielle De Jean De St. Marcel Simek-Lemos - Brooklyn NY, US

International Classification:

C07K 16/10

Abstract:

The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.